These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 20838202)

  • 1. Addressing barriers to insulin therapy: the role of insulin pens.
    Magwire ML
    Am J Ther; 2011 Sep; 18(5):392-402. PubMed ID: 20838202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for diabetes: treatment with insulin pen devices.
    Cuddihy RM; Borgman SK
    Am J Ther; 2013; 20(6):694-702. PubMed ID: 21768872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin delivery by injection in children and adolescents with diabetes.
    Hanas R; de Beaufort C; Hoey H; Anderson B
    Pediatr Diabetes; 2011 Aug; 12(5):518-26. PubMed ID: 21481121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence.
    Asche CV; Shane-McWhorter L; Raparla S
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S101-8. PubMed ID: 20515297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin pens: the modern delivery devices.
    Baruah MP
    J Assoc Physicians India; 2011 Apr; 59 Suppl():38-40. PubMed ID: 21823254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes.
    Garg S; Kelly WC; Garg S
    Expert Rev Med Devices; 2008 Mar; 5(2):113-23. PubMed ID: 18331174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use.
    Perfetti R
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S79-85. PubMed ID: 20515312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empowering people with diabetes: improving perceptions and outcomes with technical advances in insulin pens.
    Oyer D; Niemeyer M; Moses A
    Postgrad Med; 2012 Sep; 124(5):110-20. PubMed ID: 23095431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of insulin pen devices.
    McCoy EK; Wright BM
    Postgrad Med; 2010 May; 122(3):81-8. PubMed ID: 20463417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens.
    Brunton S
    Diabetes Technol Ther; 2008 Aug; 10(4):247-56. PubMed ID: 18715198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
    Eby EL; Boye KS; Lage MJ
    J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humalog(®) KwikPen™: an insulin-injecting pen designed for ease of use.
    Schwartz SL; Ignaut DA; Bodie JN
    Expert Rev Med Devices; 2010 Nov; 7(6):735-43. PubMed ID: 21050084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiating and intensifying insulin therapy for type 2 diabetes: why, when, and how.
    Cobble ME
    Am J Ther; 2009; 16(1):56-64. PubMed ID: 19142156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing insulin vials to pens--comparison of charges, not healthcare benefits.
    Thethi TK
    J Med Econ; 2013 Oct; 16(10):1228-30. PubMed ID: 23926888
    [No Abstract]   [Full Text] [Related]  

  • 16. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
    Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
    Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin pens vs. vials and syringes: differences in clinical and economic outcomes.
    Bastian MD; Wolters NE; Bright DR
    Consult Pharm; 2011 Jun; 26(6):426-9. PubMed ID: 21628141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of insulin delivery pen devices.
    Kroon L
    J Am Pharm Assoc (2003); 2009; 49(5):e118-31. PubMed ID: 19692314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose accuracy and injection force dynamics of a novel disposable insulin pen.
    Clarke A; Spollett G
    Expert Opin Drug Deliv; 2007 Mar; 4(2):165-74. PubMed ID: 17335413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study.
    Haak T; Edelman S; Walter C; Lecointre B; Spollett G
    Clin Ther; 2007 Apr; 29(4):650-60. PubMed ID: 17617288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.